Compare · HSCS vs STE
HSCS vs STE
Side-by-side comparison of HeartSciences Inc. (HSCS) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSCS and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.50B, about 3498.3x HSCS ($5.9M).
- Over the past year, HSCS is down 35.6% and STE is down 13.5% - STE leads by 22.1 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 3 for HSCS).
- STE has more recent analyst coverage (16 ratings vs 0 for HSCS).
- Company
- HeartSciences Inc.
- STERIS plc (Ireland)
- Price
- $2.20+3.29%
- $210.04-1.01%
- Market cap
- $5.9M
- $20.50B
- 1M return
- +5.77%
- -1.87%
- 1Y return
- -35.58%
- -13.48%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 3
- 39
- Recent ratings
- 0
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest HSCS
- HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
- SEC Form 253G2 filed by HeartSciences Inc.
- HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
- HeartSciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
- SEC Form QUALIF filed by HeartSciences Inc.
- SEC Form 253G2 filed by HeartSciences Inc.
- HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
- SEC Form 1-A POS filed by HeartSciences Inc.
- HeartSciences Inc. filed SEC Form 8-K: Leadership Update
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)